World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
68
Citations
13695
World Ranking
2626
National Ranking
1251

Anna P. Durbin publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Anna P. Durbin sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 183 publications — 28th percentile

28% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Anna P. Durbin D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Anna P. Durbin sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 68 D-Index — 49th percentile

49% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Anna P. Durbin is affiliated with Johns Hopkins University in the United States and primarily publishes research in the field of Medicine. Their work focuses extensively on Public Health, Environmental and Occupational Health, Infectious Diseases, and Epidemiology, with additional contributions in Health and Modeling and Simulation.

The scientist's research thèmes concentrate on mosquito-borne diseases and control, viral infections and vectors, malaria research and control, viral infections and outbreaks research, virology and viral diseases, SARS-CoV-2 and COVID-19 research, as well as vaccine coverage and hesitancy.

Frequent coauthors in their publications include:

  • Stephen S. Whitehead
  • Sean A. Diehl
  • Beth D. Kirkpatrick
  • Kristen K. Pierce
  • Usha K. Nivarthi

Their research has appeared in a range of publication venues, notably:

  • UNC Libraries
  • The Lancet Infectious Diseases
  • Nature Communications
  • Biologicals
  • Journal of Virology

Recent published papers include:

  • US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021 (2021, JAMA)
  • Dengue: A Growing Problem With New Interventions (2022, PEDIATRICS)
  • Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial (2020, The Lancet Infectious Diseases)
  • T Cell Responses Induced by Attenuated Flavivirus Vaccination Are Specific and Show Limited Cross-Reactivity with Other Flavivirus Species (2020, Journal of Virology)
  • A tetravalent live attenuated dengue virus vaccine stimulates balanced immunity to multiple serotypes in humans (2021, Nature Communications)

Best Publications

  • Prospects for a dengue virus vaccine.

    Stephen S. Whitehead;Joseph E. Blaney;Anna P. Durbin;Brian R. Murphy

  • Phase 1 Trial of Malaria Transmission Blocking Vaccine Candidates Pfs25 and Pvs25 Formulated with Montanide ISA 51

    Yimin Wu;Ruth D. Ellis;Donna Shaffer;Erica Fontes

  • US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021

    Isaac See;John R. Su;Allison Lale;Emily Jane Woo

  • Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region.

    Anna P. Durbin;Ruth A. Karron;Wellington Sun;David W. Vaughn

  • Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine.

    Ann R Falsey;Magdalena E Sobieszczyk;Ian Hirsch;Stephanie Sproule

  • Phase 1 Clinical Trial of Apical Membrane Antigen 1: an Asexual Blood-Stage Vaccine for Plasmodium falciparum Malaria

    Elissa M. Malkin;David J. Diemert;Julie H. McArthur;John R. Perreault

  • Phenotyping of peripheral blood mononuclear cells during acute dengue illness demonstrates infection and increased activation of monocytes in severe cases compared to classic dengue fever

    Anna P. Durbin;Maria José Vargas;Kimberli Wanionek;Samantha N. Hammond

  • Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria.

    Elissa M. Malkin;Anna P. Durbin;David J. Diemert;Jetsumon Sattabongkot

  • The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model

    Beth D. Kirkpatrick;Stephen S. Whitehead;Kristen K. Pierce;Cecilia M. Tibery

  • Dengue viruses cluster antigenically but not as discrete serotypes

    Leah C. Katzelnick;Judith M. Fonville;Judith M. Fonville;Judith M. Fonville;Gregory D. Gromowski;Jose Bustos Arriaga

  • Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults

    Beth D. Kirkpatrick;Anna P. Durbin;Kristen K. Pierce;Marya P. Carmolli

  • Maturation of West Nile Virus Modulates Sensitivity to Antibody-Mediated Neutralization

    Steevenson Nelson;Christiane A. Jost;Qinq Xu;Jessica Ess

  • Prior Dengue Virus Exposure Shapes T Cell Immunity to Zika Virus in Humans.

    Alba Grifoni;John Pham;John Sidney;Patrick H O'Rourke

  • A dynamic landscape for antibody binding modulates antibody-mediated neutralization of West Nile virus.

    Kimberly A. Dowd;Christiane A. Jost;Anna P. Durbin;Stephen S. Whitehead

  • A Single Dose of Any of Four Different Live Attenuated Tetravalent Dengue Vaccines Is Safe and Immunogenic in Flavivirus-naive Adults: A Randomized, Double-blind Clinical Trial

    Anna P. Durbin;Beth D. Kirkpatrick;Kristen K. Pierce;Daniel Elwood

  • The human CD8+ T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes

    Daniela Weiskopf;Michael A. Angelo;Derek J. Bangs;John Sidney

  • rDEN4Δ30, a Live Attenuated Dengue Virus Type 4 Vaccine Candidate, Is Safe, Immunogenic, and Highly Infectious in Healthy Adult Volunteers

    Anna P. Durbin;Stephen S. Whitehead;Julie McArthur;John R. Perreault

  • The dengue vaccine pipeline: Implications for the future of dengue control

    Lauren M. Schwartz;M. Elizabeth Halloran;Anna P. Durbin;Ira M. Longini

  • Pregnant women & vaccines against emerging epidemic threats: Ethics guidance for preparedness, research, and response

    Carleigh B Krubiner;Ruth R Faden;Ruth A Karron;Margaret O Little

  • Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve Adults.

    Kawsar R. Talaat;Ruth D. Ellis;Janet Hurd;Autumn Hentrich

  • Mutations in the C, D, and V Open Reading Frames of Human Parainfluenza Virus Type 3 Attenuate Replication in Rodents and Primates

    Anna P. Durbin;Josephine M. McAuliffe;Peter L. Collins;Brian R. Murphy

Frequent Co-Authors

Stephen S. Whitehead
Stephen S. Whitehead National Institute of Allergy and Infectious Diseases
Alessandro Sette
Alessandro Sette La Jolla Institute For Allergy & Immunology
Aravinda M. de Silva
Aravinda M. de Silva University of North Carolina at Chapel Hill
Daniela Weiskopf
Daniela Weiskopf La Jolla Institute For Allergy & Immunology
Eva Harris
Eva Harris University of California, Berkeley
Brian R. Murphy
Brian R. Murphy National Institute of Allergy and Infectious Diseases
Louis H. Miller
Louis H. Miller National Institute of Allergy and Infectious Diseases
Ralph S. Baric
Ralph S. Baric University of North Carolina at Chapel Hill
Alba Grifoni
Alba Grifoni La Jolla Institute For Allergy & Immunology
Angel Balmaseda
Angel Balmaseda University of California, Berkeley

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those studying Immunology in the USA, exploring related healthcare degrees can open up diverse career pathways. Many students consider transitioning into nursing roles, which complement immunological expertise with patient care skills. For example, nurses can advance their practice by pursuing an acute care certification for FNP, allowing them to specialize in critical and complex patient care.

Accelerated degree options make it easier to quickly meet career goals. Programs like accelerated FNP programs provide a fast-tracked route to becoming a Family Nurse Practitioner, blending clinical experience with expanded responsibilities. Similarly, those without a nursing background can enter the field through some of the best online BSN programs for non nurses, which offer foundational nursing education accessible from anywhere.

For quicker entry into nursing, the 12-month accelerated nursing programs stand out for their condensed curriculum and efficient format. These programs are ideal for individuals seeking to transition into nursing within a year while maintaining high educational standards.

By leveraging these online degree options, students and professionals in immunology can broaden their expertise and expand their impact in healthcare settings. Each pathway offers unique benefits, catering to different career goals and timelines.

Learn more about acute care certification for fnp, explore top accelerated fnp programs, discover the best online bsn programs for non nurses, and consider fast-tracking your career with 12-month accelerated nursing programs.

Best Scientists Citing Anna P. Durbin

Trending Scientists

Recently Published Articles